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The Mortality Burden of Idiopathic Pulmonary Fibrosis in the United Kingdom 
To the Editor, 
We have previously demonstrated that mortality from idiopathic pulmonary fibrosis (IPF) is on the 
rise in the UK (1) and globally.(2) Although numerous clinical trials, genetic and metabolomics 
studies have provided insight, large epidemiological studies on disease burden remains limited. This 
is particularly important now that therapeutic options for IPF are available. Despite its limitations, 
registered deaths from IPF are a pragmatic and validated(3) way of assessing and providing reliable 
estimates of disease burden in terms of mortality. The aim of our study was to provide up to date IPF 
mortality rate estimates and changes to trends in the UK.  
Methods 
Data source  
We used routine mortality data from England and Wales obtained from the Office of National 
Statistics (ONS) (4) which is derived from registered death certificates and coded for the underlying 
cause of death.(5)  The accuracy of coding of underlying cause of deaths is high.(6)  
We used the term IPF clinical syndrome (IPF-CS) (1, 7) when using routinely collected clinical data, to 
acknowledge the difficulty in demonstrating that our study population meets ATS/ERS diagnostic 
criteria. (8) 
Statistical analysis 
We obtained annual number of deaths from IPF-CS stratified by age and sex for the years 1979 to 
2016. During our study period, deaths were coded using different International Classification of 
Diseases (ICD) codes; from 1979 to 2000 ICD-9 codes 515 (post inflammatory fibrosis) and 516.3 
(idiopathic fibrosing alveolitis) were used and from 2001 onwards it was ICD-10 code J84.1 
(idiopathic pulmonary fibrosis). We extracted general population estimates for the same period.  All 
data were grouped into 5-6 year periods, but without combining the different ICD codes, and 5 year 
age groups over the age of 55. 
Crude mortality rates stratified by age, sex and calendar period were estimated.  We used direct 
standardization to calculate age-standardized mortality rates, standardized to the 2016 population 
of England and Wales. We performed a sub-analysis of the two different ICD-9 codes for IPF-CS (ICD-
9 code 515 and ICD-9 code 516.3). Poisson regression was used to estimate mortality rate ratios, 
adjusting for age and sex. We explored effect modification between trends in annual mortality rates 
with age and sex. Likelihood ratio tests were used for hypothesis testing.  Stata v15 (StataCorp, 
College Station, TX) was used for all statistical analyses.  
Results 
A total of 82,702 deaths were attributed to IPF-CS in England and Wales from 1979 to 2016.  The 
overall age-standardized mortality rate for this period was 4.68 per 100,000 person-years (95% 
Confidence Interval [CI] 4.64 to 4.71). Age-standardized mortality rates increased from 1.66 (95% CI 
1.54 to 1.79) in 1979 to 8.29 (95% CI 8.06 to 8.53) per 100,000 person-years in 2016 (see Figure 1). 
The annual increase in the number of IPF-CS deaths, after adjusting for age and sex was 
approximately 5% (Rate Ratio [RR] 1.050, 95% CI 1.049 to 1.051; p<0.001). Age-standardized 
mortality rates were higher in men and the elderly (See Table 1). There was also strong evidence of 
effect modification by age (p<0.001) and sex (p<0.001). The increase in annual mortality rates was 
highest amongst men (RR per year 1.052, 95% CI 1.051 to 1.053) and over 85s (RR per year 1.094, 
95% CI 1.092 to 1.096). 
 
 
 
Sub-analysis of ICD-9 codes 
From 1979 to 2000 there were 12,989 deaths from post-inflammatory fibrosis (ICD-9 code 515) and 
16,989 deaths from idiopathic fibrosing alveolitis (ICD-9 code 516.3). The age-standardized mortality 
rates for both ICD-9 codes increased during this period. For post-inflammatory fibrosis, the age-
standardized mortality rate increased from 0.92 (95% CI 0.88 to 0.97) per 100,000 person-years in 
the 1979 to 1983 calendar period to 1.77 (95% CI 1.72 to 1.82) per 100,000 person-years in the 1995 
to 2000 calendar period. Age-standardized mortality rates for idiopathic fibrosing alveolitis increased 
from 0.88 (95% CI 0.84 to 0.92) to 2.41 (2.35 to 2.47) per 100,000 person-years for the same 
calendar periods. Yearly mortality increased by 4.4% (RR 1.044, 95% CI 1.041 to 1.047) for post-
inflammatory fibrosis and 6.3% (RR 1.063, 95% CI 1.060 to 1.066) for idiopathic fibrosing alveolitis, 
after controlling for age and sex.  
Figure 1: Age-standardized mortality rates for idiopathic pulmonary fibrosis clinical syndrome (IPF-
CS) in England and Wales from 1979 to 2016. 
 
Table 1: Age-standardized mortality rates and mortality rate ratios of deaths from idiopathic 
pulmonary fibrosis clinical syndrome 
 Number 
of deaths 
Person-
years 
(million) 
Crude mortality rate 
per 100,000 person-
years (95% CI) 
Age- standardized 
mortality rate per 
100,000 person -
years (95% CI) 
Adjusted 
mortality rate 
ratio (95% CI)* 
Calendar 
period 
     
ICD-9      
1979-1983 3858 248 1.56 (1.51-1.61) 1.81 (1.75-1.86) 1.00 
1984-1988 5888 250 2.36 (2.30-2.42) 2.71 (2.64-2.78) 1.53 (1.47-
1.59) 
1989-1994 8640 305 2.84 (2.78-2.90) 3.21 (31.4-3.28) 1.87 (1.80-
1.94) 
1995-2000 11577 310 3.73 (3.67-3.80) 4.18 (4.10-4.25) 2.50 (2.41-
2.59) 
ICD-10      
2001-2005 12197 265 4.61 (4.53-4.69) 5.07 (4.98-5.16) 3.16 (3.05-
3.28) 
2006-2010 14677 274 5.35 (5.27-5.44) 5.77 (5.68-5.87) 3.80 (3.67-
3.94) 
2011-2016 25865 343 7.53 (7.44-7.63) 7.71 (7.62-7.81) 5.59 (5.40-
5.78) 
Sex      
Male 50912 975 5.22 (5.18-5.27) 7.41 (7.34-7.48) 2.03 (1.99-
2.05) 
Female 31790 1020 3.12 (3.08-3.15) 2.99 (2.96-3.02) 1.00 
Age group 
(years) 
     
<54 2499 1460 0.17 (0.16-0.18) 0.17 (0.16-0.18) 0.002 (0.001-
0.003) 
55-59 2599 113 2.30 (2.21-2.39) 2.30 (2.21-2.39) 0.26 (0.25-
0.28) 
60-64 4952 105 4.71 (4.58-4.85) 4.71 (4.59-4.84) 0.58 (0.56-
0.60) 
65-69 8837 95.3 9.27 (9.08-9.47) 9.27 (9.08-9.47) 1.00 
70-74 13294 81 16.41 (16.13-16.69) 16.41 (16.13-
16.69) 
1.93 (1.87-
1.98) 
75-79 17030 64.4 26.45 (26.05-26.84) 26.45 (26.05-
26.84) 
3.31 (3.23-
3.40) 
80-84 16541 44.2 37.45 (36.88-38.02) 37.45 (36.88-
38.02) 
4.38 (4.27-
4.49) 
≥85 16950 35.5 47.78 (47.06-48.50) 47.78 (47.06-
48.50) 
4.83 (4.71-
4.95) 
*Mortality rate ratios adjusted for all other variables in the table 
 
 
Discussion 
This study demonstrates that mortality from IPF-CS continues to rise by 5% per year after accounting 
for an ageing population. We found a marked increase in IPF-CS deaths from 2010 onwards, with 
IPF-CS mortality in 2016 being 51% higher than 2010. Sub-analysis of the ICD-9 codes showed that 
age-standardized mortality rates increased for both codes. Registered deaths were highest in men 
and the elderly, which is consistent with previous studies.(1, 2) Based on these findings we estimate 
that approximately 5,500 people die from IPF-CS in the UK each year.  
One strength of our study is the large number of registered deaths and long study period, which 
enabled us to estimate precise changes to mortality trends and stratify our results by sex, age and 
calendar period. We were also able to explore if the annual increase in mortality was modified by 
age or sex. A possible limitation is the validity of diagnosis of IPF. However, previous studies have 
demonstrated a high diagnostic accuracy for death certification of lung fibrosis.(2, 3, 9) Furthermore, 
we recently showed that only two-thirds of people with IPF have it recorded as their underlying 
cause of death and 80% had it mentioned anywhere on their death certificate (2) suggesting that our 
results are an under-estimate of the mortality burden and incidence of IPF in the UK. We were not 
able to evaluate how changes from ICD-9 to ICD-10 coding impacted mortality trends. Data from the 
ONS suggest that the number of deaths assigned to the respiratory chapter as a whole decreased by 
22% as a result of the introduction of ICD-10 codes, largely driven by the decrease in number of 
deaths assigned to pneumonia.(10) It is possible that this may have resulted in further under-
estimating the actual number of IPF-CS related deaths.  
These findings are consistent with our work demonstrating a progressive rise in IPF mortality in the 
UK. (1, 2, 11) Increased case ascertainment could be a contributing factor to the trends seen, but it is 
also possible that the true incidence of IPF has continued to increase.  If the marked increase in 
number of deaths is purely due to increased disease recognition, there is no evidence that 
ascertainment is complete, and continued upward trends in mortality are likely to be seen.  
In summary, IPF-CS now accounts for almost 7% of all respiratory deaths in the UK (4) and carries the 
same mortality burden as liver, bladder and intracranial malignancies. Despite increasing research 
investment, it remains an important cause of respiratory mortality and a growing public health 
problem.                                                                                                                                            
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